“…101 While cognitive aging and neurodegenerative diseases such as AD have emerged as a brain or CNS manifestation of metabolic diseases, 102 recent studies in large human cohorts revealed reduced circulating levels of Pls in metabolic diseases, including obesity, hypertension, pre-diabetes, type 2 diabetes, and non-alcoholic fatty liver disease. 103 Among the underlying mechanisms, multiple pathways were pointed out, including the disruption of cellular and mitochondrial membranes, increased oxidative stress, ER dysfunction, and inflammation. 103 Changes in cellular metabolism, from the highly efficient oxidative phosphorylation (taking place in mitochondria) to glycolysis (in cytosol), notably occurring when mitochondrial structure and function is compromised, 85,86,104 were also linked to microglial dysfunction and reactivity, together with impaired synaptic plasticity and cognitive aging in mice.…”